Get the Stockscreener App
1.035
0.98%
0.01
After Hours:
1.04
0.005
+0.48%
Achilles Therapeutics Plc Adr stock is traded at $1.035, with a volume of 106.83K.
It is up +0.98% in the last 24 hours and up +0.86% over the past month.
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
See More
Previous Close:
$1.025
Open:
$1.01
24h Volume:
106.83K
Relative Volume:
0.17
Market Cap:
$42.12M
Revenue:
-
Net Income/Loss:
$-63.97M
P/E Ratio:
-0.575
EPS:
-1.8
Net Cash Flow:
$-62.91M
1W Performance:
+4.01%
1M Performance:
+0.86%
6M Performance:
+28.78%
1Y Performance:
+19.89%
1-Day Range:
$1.00
$1.05
1-Week Range:
$0.9753
$1.05
52-Week Range:
$0.63
$1.76
Achilles Therapeutics Plc Adr Stock (ACHL) Company Profile
Name
Achilles Therapeutics Plc Adr
Sector
Industry
Phone
-
Address
-
Achilles Therapeutics Plc Adr Stock (ACHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | Chardan Capital Markets | Buy |
| Apr-26-21 | Initiated | JP Morgan | Underweight |
| Apr-26-21 | Initiated | Oppenheimer | Outperform |
| Apr-26-21 | Initiated | Piper Sandler | Overweight |
Achilles Therapeutics Plc Adr Stock (ACHL) Latest News
ACHL’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Check Out Achilles Therapeutics Plc ADR (ACHL)’s Trade Data Rather Than the Analysts’ Views - SETE News
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
why Achilles Therapeutics Plc ADR [ACHL] is a Good Choice for Investors After New Price Target of $1.25 - The DBT News
What Analysts Were Expecting After PowerFleet Inc (NASDAQ: AIOT) rose 2.40% - Stocks Register
Achilles Thera shifts focus to new cancer treatment avenues - The Pharma Letter
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
You Should Read This Analysis Before Investing in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) - US Post News
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Achilles Therapeutics Announces Strategic Update - Yahoo Finance
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates - GlobeNewswire Inc.
Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why - Yahoo New Zealand News
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why - Yahoo Sport Australia
Achilles Therapeutics Plc ADR (ACHL) Clearly Signals Buy-Into the Stock: Don't ignore the signals – Sete News - SETE News
Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study - Yahoo Lifestyle UK
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study - Yahoo Movies UK
Waters (WAT) Walk-Up Solutions Boost Bioprocess Development - Yahoo Lifestyle UK
Achilles Therapeutics and Arcturus team up for cancer vaccine By Investing.com - Investing.com
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation ... - GlobeNewswire
Achilles Therapeutics Announces Research Collaboration with - GlobeNewswire
Achilles Therapeutics faces Nasdaq delisting over share price - Investing.com
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 - Yahoo New Zealand News
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs - Yahoo Movies UK
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study - Yahoo News UK
Achilles Therapeutics Plc ADR's Shares Reel: -0.12% Quarterly Revenue Decline Amid 37.75M Market Cap – Invest ... - The InvestChronicle
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC ... - GlobeNewswire
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference - GlobeNewswire
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights - GlobeNewswire
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation - Quantisnow
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock - Yahoo Finance
Apellis (APLS) Up More Than 60% in Past 3 Months: Here's Why - Nasdaq
Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 - Yahoo Finance
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity - Yahoo Finance Australia
Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board - GlobeNewswire
Achilles Therapeutics PlcADR Shares Close the Day 10.1% HigherDaily Wrap - Nasdaq
Achilles Therapeutics Announces Pricing of Initial Public Offering - GlobeNewswire
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Achilles Therapeutics Plc Adr Stock (ACHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):